Phase II study of dose-dense doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/NEU-overexpressed/amplified breast cancer: Feasibility.

Trial Profile

Phase II study of dose-dense doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/NEU-overexpressed/amplified breast cancer: Feasibility.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 May 2017

At a glance

  • Drugs Cyclophosphamide; Doxorubicin; Lapatinib; Paclitaxel; Pegfilgrastim; Trastuzumab
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Mar 2013 Additional lead trial center added as reported by ClinicalTrials.gov.
    • 27 Jul 2010 Planned end date changed from 1 Mar 2009 to 1 Mar 2010 as reported by ClinicalTrials.gov.
    • 13 Oct 2008 Status changed from recruiting to active, no longer recruiting, based on information from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top